Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Open-label Dose-escalation Study of Intravenous Aflibercept (AVE0005, VEGF Trap) in Combination With R-CHOP Administered Every 2 Weeks or Every 3 Weeks in Patients With Non Hodgkin's B-cell Lymphoma

NCT00644124 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT00644124
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00644124 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Open-label Dose-escalation Study of Intravenous Aflibercept (AVE0005, VEGF Trap) in Combination With R-CHOP Administered Every 2 Weeks or Every 3 Weeks in Patients With Non Hodgkin's B-cell Lymphoma
Lead sponsor
Sanofi
Phase
Phase 1
Overall status
Completed
Start date
March 31, 2008
Completion date
October 31, 2011
Enrollment
25 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma, non-hodgkin